100 related articles for article (PubMed ID: 35355155)
1. Development of a prognostic metabolic signature in stomach adenocarcinoma.
Gong Y; Wu S; Dong S; Chen S; Cai G; Bao K; Yang H; Jiao Y
Clin Transl Oncol; 2022 Aug; 24(8):1615-1630. PubMed ID: 35355155
[TBL] [Abstract][Full Text] [Related]
2. Single-cell data revealed CD14-type and FCGR3A-type macrophages and relevant prognostic factors for predicting immunotherapy and prognosis in stomach adenocarcinoma.
Li M; Lu M; Li J; Gui Q; Xia Y; Lu C; Shu H
PeerJ; 2024; 12():e16776. PubMed ID: 38274323
[TBL] [Abstract][Full Text] [Related]
3. A Five-gene Signature based on MicroRNA for Predicting Prognosis and Immunotherapy in Stomach Adenocarcinoma.
Wang T; Chen P; Li T; Li J; Zhao D; Meng F; Zhao Y; Zheng Z; Liu X
Curr Med Chem; 2024; 31(17):2378-2399. PubMed ID: 38310388
[TBL] [Abstract][Full Text] [Related]
4. Construction of a prognostic risk model for Stomach adenocarcinoma based on endoplasmic reticulum stress genes.
Li X; Lei Y
Wien Klin Wochenschr; 2024 Jun; 136(11-12):319-330. PubMed ID: 37993598
[TBL] [Abstract][Full Text] [Related]
5. A 9‑gene expression signature to predict stage development in resectable stomach adenocarcinoma.
Liu Z; Liu H; Wang Y; Li Z
BMC Gastroenterol; 2022 Oct; 22(1):435. PubMed ID: 36241983
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of RNA methylation-related genes in gastric adenocarcinoma based on bioinformatics.
He X; Chen X; Yang C; Wang W; Sun H; Wang J; Fu J; Dong H
PeerJ; 2024; 12():e16951. PubMed ID: 38436027
[TBL] [Abstract][Full Text] [Related]
7. Identification and Validation of a Cancer-Testis Antigen-Related Signature to Predict the Prognosis in Stomach Adenocarcinoma.
Bian G; Cao J; Li W; Huang D; Ding X; Zang X; Ye Y; Li P
J Cancer; 2024; 15(11):3596-3611. PubMed ID: 38817874
[No Abstract] [Full Text] [Related]
8. Identification of necroptosis-associated miRNA signature for predicting prognosis and immune landscape in stomach adenocarcinoma.
Zhang S; Liu S; Yue C; Liu Y; Zheng G; Zhang Y
Exp Cell Res; 2024 Mar; 436(1):113948. PubMed ID: 38307189
[TBL] [Abstract][Full Text] [Related]
9. Potential Prognostic Value and Mechanism of Stromal-Immune Signature in Tumor Microenvironment for Stomach Adenocarcinoma.
Zhu X; Xie X; Zhao Q; Zhang L; Li C; Zhao D
Biomed Res Int; 2020; 2020():4673153. PubMed ID: 32685487
[TBL] [Abstract][Full Text] [Related]
10. Development of an immunogenic cell death prognostic signature for predicting clinical outcome and immune infiltration characterization in stomach adenocarcinoma.
Liu Y; Zhang L; Lei X; Yin X; Liu S
Aging (Albany NY); 2023 Oct; 15(20):11389-11411. PubMed ID: 37862109
[TBL] [Abstract][Full Text] [Related]
11. ASF1B acted as a prognostic biomarker for stomach adenocarcinoma.
Zhao C; Zhou J; Xing J; Yin Q
Medicine (Baltimore); 2023 Dec; 102(48):e35408. PubMed ID: 38050219
[TBL] [Abstract][Full Text] [Related]
12. A Prognostic Signature Constructed by
Han S; Zhu W; Yang W; Guan Q; Chen C; He Q; Zhong Z; Zhao R; Xiong H; Han H; Li Y; Sun Z; Hu X; Tian J
Front Genet; 2021; 12():646818. PubMed ID: 34512711
[TBL] [Abstract][Full Text] [Related]
13. A ubiquitination-related risk model for predicting the prognosis and immunotherapy response of gastric adenocarcinoma patients.
Shao S; Sun Y; Zhao D; Tian Y; Yang Y; Luo N
PeerJ; 2024; 12():e16868. PubMed ID: 38313020
[TBL] [Abstract][Full Text] [Related]
14. Immunobiological signatures and the emerging role of SPP1 in predicting tumor heterogeneity, malignancy, and clinical outcomes in stomach adenocarcinoma.
Wu Y; Ren L; Tang Y; Zhu Z; Liu S; Jiang Y; Zhang S; Zhuang X; Chen Y
Aging (Albany NY); 2023 Oct; 15(20):11588-11610. PubMed ID: 37889539
[TBL] [Abstract][Full Text] [Related]
15. GPX3-Mediated Oxidative Stress Affects Pyrimidine Metabolism Levels in Stomach Adenocarcinoma via the AMPK/mTOR Pathway.
Zhang Y; Yang Y; Kuang S; Zhang Y; Qin H; Xie J
Int J Clin Pract; 2024; 2024():6875417. PubMed ID: 38322113
[TBL] [Abstract][Full Text] [Related]
16. Establishment of the molecular subtypes and a risk model for stomach adenocarcinoma based on genes related to reactive oxygen species.
Li G; Ping M; Zhang W; Wang Y; Zhang Z; Su Z
Heliyon; 2024 Mar; 10(5):e27079. PubMed ID: 38463816
[TBL] [Abstract][Full Text] [Related]
17. Molecular subtype construction and prognosis model for stomach adenocarcinoma characterized by metabolism-related genes.
Sun J; Wang Y; Zhang K; Shi S; Gao X; Jia X; Cong B; Zheng C
Heliyon; 2024 Apr; 10(7):e28413. PubMed ID: 38596054
[TBL] [Abstract][Full Text] [Related]
18. A degradome-related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma based on machine learning procedure.
Deng Z; Feng Q; Zhao D; Huang Z
Medicine (Baltimore); 2024 Apr; 103(15):e37728. PubMed ID: 38608069
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value and therapeutic potential of NEK family in stomach adenocarcinoma.
Zhou X; Nie H; Wang C; Yu X; Yang X; He X; Ou C
J Cancer; 2024; 15(10):3154-3172. PubMed ID: 38706902
[TBL] [Abstract][Full Text] [Related]
20. Analysis of IGFBP7 expression characteristics in pan-cancer and its clinical relevance to stomach adenocarcinoma.
Xu HW; Wang MQ; Zhu SL
Transl Cancer Res; 2023 Oct; 12(10):2596-2612. PubMed ID: 37969374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
